These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees. Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881 [TBL] [Abstract][Full Text] [Related]
4. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. Johnston MS; Galan A; Watsky KL; Little AJ JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670 [TBL] [Abstract][Full Text] [Related]
5. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. Larson V; Seidenberg R; Caplan A; Brinster NK; Meehan SA; Kim RH J Cutan Pathol; 2022 Jan; 49(1):34-41. PubMed ID: 34292611 [TBL] [Abstract][Full Text] [Related]
6. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous manifestations of COVID-19 and COVID-19 vaccination. Nakashima C; Kato M; Otsuka A J Dermatol; 2023 Mar; 50(3):280-289. PubMed ID: 36636825 [TBL] [Abstract][Full Text] [Related]
8. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Bookstein Peretz S; Regev N; Novick L; Nachshol M; Goffer E; Ben-David A; Asraf K; Doolman R; Levin EG; Regev Yochay G; Yinon Y Ultrasound Obstet Gynecol; 2021 Sep; 58(3):450-456. PubMed ID: 34198360 [TBL] [Abstract][Full Text] [Related]
9. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status. Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR Elife; 2021 Oct; 10():. PubMed ID: 34636722 [TBL] [Abstract][Full Text] [Related]
10. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. McMahon DE; Amerson E; Rosenbach M; Lipoff JB; Moustafa D; Tyagi A; Desai SR; French LE; Lim HW; Thiers BH; Hruza GJ; Blumenthal KG; Fox LP; Freeman EE J Am Acad Dermatol; 2021 Jul; 85(1):46-55. PubMed ID: 33838206 [TBL] [Abstract][Full Text] [Related]
11. Assessment of Delayed Large Local Reactions After the First Dose of the SARS-CoV-2 mRNA-1273 Vaccine in Japan. Higashino T; Yamazaki Y; Senda S; Satou Y; Yonekura Y; Imai K; Arakawa J; Kawano S; Horinosono H; Miura Y JAMA Dermatol; 2022 Aug; 158(8):923-927. PubMed ID: 35649530 [TBL] [Abstract][Full Text] [Related]
12. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older. Choi YY; Kim MK; Kwon HC; Kim GH J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980 [TBL] [Abstract][Full Text] [Related]
13. COVID arm as a common cutaneous manifestation after mRNA-1273 vaccination: a systematic review. Agustin M; Trifitriana M; Danarti R BMC Infect Dis; 2023 Jan; 23(1):7. PubMed ID: 36609222 [TBL] [Abstract][Full Text] [Related]